These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 6803557)

  • 21. Compounding legislation clears first Senate hurdle.
    Traynor K
    Am J Health Syst Pharm; 2013 Jul; 70(13):1094-6. PubMed ID: 23784150
    [No Abstract]   [Full Text] [Related]  

  • 22. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
    Green W
    Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
    [No Abstract]   [Full Text] [Related]  

  • 23. Doctors are focus of some sweeping changes being dusted off in Drug Reform Act.
    Hornett P
    Leg Aspects Med Pract; 1978 Aug; 6(8):54-7. PubMed ID: 703483
    [No Abstract]   [Full Text] [Related]  

  • 24. PDA response. FDA advance notice of proposed rulemaking on electronic identification/signatures. Parenteral Drug Association.
    J Parenter Sci Technol; 1993; 47(1):4-8. PubMed ID: 8445499
    [No Abstract]   [Full Text] [Related]  

  • 25. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 26. Regulating drugs for effectiveness and safety: a public health perspective.
    Zito JM; Socolar SJ; Eilers R; Crystal S; Lexchin J
    Med Care; 2007 Sep; 45(9):911. PubMed ID: 17712264
    [No Abstract]   [Full Text] [Related]  

  • 27. ASHP guidelines for institutional use of controlled substances.
    Am J Hosp Pharm; 1974 Jun; 31(6):582-8. PubMed ID: 4407475
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs.
    Patsner B
    Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473
    [No Abstract]   [Full Text] [Related]  

  • 29. Package inserts, adverse drug reactions, and the physician's liability.
    Morrell MX
    Ration Drug Ther; 1975 Aug; 9(8):1-6. PubMed ID: 1144773
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacy--quo vadis?
    Apple WS
    Health Matrix; 1983; 1(2):63-5. PubMed ID: 10263335
    [No Abstract]   [Full Text] [Related]  

  • 31. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. American beauty: an analytical view of the past and current effectiveness of cosmetic safety regulations and future direction.
    Termini RB; Tressler L
    Food Drug Law J; 2008; 63(1):257-74. PubMed ID: 18561461
    [No Abstract]   [Full Text] [Related]  

  • 33. Off-label uses of drugs and medical devices: should the FDA crack down?
    Margolis RE
    Healthspan; 1993 Jan; 10(1):18-9. PubMed ID: 10124289
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmaceuticals: drug importation--2005. End of Year Issue Brief.
    Varma P; Seay M
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708457
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA puts forth proposal to mandate patient information.
    Wechsler J
    Formulary; 1995 Oct; 30(10):622-3. PubMed ID: 10151725
    [No Abstract]   [Full Text] [Related]  

  • 36. Hospital pharmacies watch prescriptions as debate rages over 'off-label' drug use.
    Wagner M
    Mod Healthc; 1992 May; 22(19):62. PubMed ID: 10117635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A conversation with Commissioner Jere E. Goyan, pharmacist. Interview by William E. Small.
    Goyan JE
    Am Pharm; 1980 Jan; NS20(1):19-24. PubMed ID: 7378168
    [No Abstract]   [Full Text] [Related]  

  • 38. Sounding board. Creative tension: FDA and medicine.
    Kennedy D
    N Engl J Med; 1978 Apr; 298(15):846-50. PubMed ID: 345121
    [No Abstract]   [Full Text] [Related]  

  • 39. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 40. What you should know about FDA-USP Drug Product Problem Reporting Program.
    McGinnis DM
    Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.